Every Form 4 that GENVOR INC (GNVR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GNVR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GNVR filings page.
Genvor Inc. reported that Chief Executive Officer Chad Lee Pawlak Sr. received a grant of 250,000 shares of common stock at $0.50 per share. According to the disclosure, this stock award compensates Mr. Pawlak for converting $125,000 of outstanding payables owed to him by the company under a restructured compensation package approved by the board as of December 20, 2024. Following this grant, he directly holds 7,000,000 shares of Genvor common stock.
Pawlak Chad Lee Sr. reported acquisition or exercise transactions in this Form 4 filing.
Genvor Inc Chief Executive Officer Chad Lee Pawlak Sr. received a grant of 250,000 shares of Common Stock as compensation, with a reported price of $0.0000 per share. After this award, he directly holds 6,750,000 Common Stock shares.
The footnote explains this is a compensation award for January–March 2026 under a restructured compensation package approved by the Board of Directors as of December 20, 2024.
Genvor Inc. reported that its Chief Executive Officer, director, and 10% owner, Chad Lee Pawlak Sr., received a stock compensation award of 250,000 shares of common stock on January 9, 2026. The shares were acquired at a stated price of $0.00 per share, reflecting an equity grant rather than an open-market purchase.
Following this award, Pawlak beneficially owned 6,500,000 shares of Genvor common stock directly. According to the filing, this grant represents compensation for the period from October through December 2025 under a restructured compensation package approved by the company’s board of directors on December 20, 2024.
Genvor Inc. reported that Dr. Jesse Jaynes, a director and Chief Research Officer, acquired common stock through conversions of accrued payables owed to him. On 05/08/2025, Dr. Jaynes received 400,000 shares of common stock at $0.25 per share through the conversion of $100,000 in accrued payables. On 12/02/2025, he received an additional 124,000 shares at $1.50 per share by converting $186,000 in accrued payables. After these transactions, Dr. Jaynes directly beneficially owned 524,000 shares of Genvor Inc. common stock.
Genvor Inc. reporting person Chad Lee Pawlak Sr. — who is listed as Chief Executive Officer, a Director and a 10% owner — received 250,000 shares of common stock on 10/08/2025 as a non-derivative acquisition. After the award, Pawlak beneficially owns 6,250,000 shares. The filing states the shares were a compensation award for July–September 2025, under a restructured package the board approved on 12/20/2024. The Form 4 is signed and dated 10/09/2025. No exercise prices, derivative transactions, cash values, or additional plan terms are disclosed in this filing.